New blood test could predict which colorectal cancer patients benefit from targeted drugs

NCT ID NCT07224841

Recruiting now Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study aims to develop a blood test that uses epigenetic markers (chemical changes on DNA) to predict whether a patient with metastatic colorectal cancer will respond to targeted therapies like cetuximab or bevacizumab. Researchers will analyze blood samples from 500 patients before treatment to identify patterns that separate responders from non-responders. The goal is to create a tool that helps doctors personalize treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cfDNA 5mC/5hmC sequencing and assay
What this could lead to: If successful, this could lead to a simple blood test that helps doctors choose the right targeted therapy for each patient with metastatic colorectal cancer, improving treatment outcomes.
What could go wrong: This is an early-stage study focused on developing and validating a biomarker panel. The test may not prove accurate enough in larger populations, and it does not directly treat the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRC (COLORECTAL CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRC (COLORECTAL CANCER)

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.